Diagnosis of recurrent HCC: intraindividual comparison of gadoxetic acid MRI and extracellular contrast-enhanced MRI

[1] Bruix J(2011)Management of hepatocellular carcinoma: an update Hepatology 53 1020-1022

[2] Sherman M(2008)Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma Hepatology 47 97-104

[3] Forner A(2018)AASLD guidelines for the treatment of hepatocellular carcinoma Hepatology 67 358-380

[4] Vilana R(2011)Detection of small hepatocellular carcinoma: intraindividual comparison of gadoxetic acid-enhanced MRI at 3.0 and 1.5 T Invest Radiol 46 383-389

[5] Ayuso C(2010)Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or = 2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging Invest Radiol 45 96-103

[6] Bianchi L(2017)2017 Version of LI-RADS for CT and MR Imaging: An Update Radiographics 37 1994-2017

[7] Sole M(2017)Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update Hepatol Int 11 317-370

[8] Ayuso JR(2014)CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features Radiology 273 30-50

[9] Boix L(1996)Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA Radiology 200 59-67

[10] Sala M(2010)Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma Radiology 255 459-466

[1] Bruix J(2011)Management of hepatocellular carcinoma: an update Hepatology 53 1020-1022

[2] Sherman M(2008)Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma Hepatology 47 97-104

[3] Forner A(2018)AASLD guidelines for the treatment of hepatocellular carcinoma Hepatology 67 358-380

[4] Vilana R(2011)Detection of small hepatocellular carcinoma: intraindividual comparison of gadoxetic acid-enhanced MRI at 3.0 and 1.5 T Invest Radiol 46 383-389

[5] Ayuso C(2010)Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or = 2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging Invest Radiol 45 96-103

[6] Bianchi L(2017)2017 Version of LI-RADS for CT and MR Imaging: An Update Radiographics 37 1994-2017

[7] Sole M(2017)Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update Hepatol Int 11 317-370

[8] Ayuso JR(2014)CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features Radiology 273 30-50

[9] Boix L(1996)Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA Radiology 200 59-67

[10] Sala M(2010)Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma Radiology 255 459-466